Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her‐2/neu Expression in Gastric Cancer. Issue 4 (14th February 2015)

• Record Type: Journal Article
• Authors: Cheng, Yu; Zhou, Jin; Li, Honglun
• Is Part Of: Clinical and translational science. Volume 8:Issue 4(2015)
• Page Start: 320
• Page End: 325
• Publication Date: 2015-02-14
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.12263
• Languages: English
• ISSNs: 1752-8054

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="cts12263-sec-0010" sec-type="section"> <title>Background:</title> <p>To detect the expression of eIF3f and human epidermal growth factor receptor 2 (Her‐2)/neu in gastric cancer (GC), correlation with their clinicopathological parameters and the relationship of eIF3f and Her‐2/neu in the occurrence and development of GC.</p> </sec> <sec id="cts12263-sec-0020" sec-type="section"> <title>Methods:</title> <p>A total of 195 gastrectomy specimens with stage I to III were examined for eIF3f expression by immunohistochemistry and for Her‐2/neu expression by fluorescence <italic>in situ</italic> hybridization (FISH) with the median follow‐up period of 38 months.</p> </sec> <sec id="cts12263-sec-0030" sec-type="section"> <title>Results:</title> <p>The positive expression rate of eIF3f in GC and adjacent noncancerous tissue were 33.8% and 59.5%, respectively. eIF3f levels were linked to more advanced tumor stages and likelihood of recurrence (all p < 0.05). The Kaplan–Meier survival curves indicated that decreased expression of eIF3f could serve as a prognosis marker for poor outcome of GC patients (p = 0.04). 15.9% of GC specimens were positive for Her‐2/neu, but whose expression was of no correlation with patients' survival. Patients who were positive for Her‐2/neu also had high eIF3f expression levels (p = 0.0295).</p> </sec> <sec id="cts12263-sec-0040" sec-type="section"> <title>Conclusion:</title> <p>Results suggest that eIF3f may play an important role in recurrence, thus representing a promising predictive marker for the prognosis of GC. But Her‐2/neu has no relationship with the prognosis of GC. The clinical significance of eIF3f and Her‐2/neu remains to be further investigated.</p> </sec> </abstract>